RESEARCH ARTICLE

- 2 Global seasonal activities of respiratory syncytial virus before the COVID-19 pandemic:
- 3 a systematic review

1

6

12

13

16

- 4 Songwei Shan^{1,2}, Weixin Zhang¹, Huizhi Gao¹, Pei-Yu Huang¹, Zhanwei Du^{1,2}, Yuan Bai^{1,2},
- 5 Yiu-Chung Lau^{1,2}, Dongxuan Chen^{1,2}, Eric HY Lau^{1,2}, Joshua Nealon¹, Peng Wu^{1,2}
- ¹World Health Organization Collaborating Centre for Infectious Disease Epidemiology and
- 8 Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong
- 9 Kong, Hong Kong SAR, China.
- ²Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong
- 11 Kong SAR, China.
- 14 Corresponding author: Peng Wu, School of Public Health, The University of Hong Kong,
- 15 email: pengwu@hku.hk, Tel: 3917 6746
- 17 Running head: Global RSV seasonality
- 19 Word count (Abstract): 248
- Word count (main text): 3,356
- 21 Keywords: activity, respiratory syncytial virus, seasonality, global

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

data reporting.

ABSTRACT

Background: Varied seasonal patterns of respiratory syncytial virus (RSV) have been reported worldwide. We aimed to review the patterns of RSV activity globally before the COVID-19 pandemic and to explore factors potentially associated with RSV seasonality. **Methods:** We conducted a systematic review on articles identified in PubMed reporting RSV seasonality based on data collected before 1 January 2020. Information on the timing of the start, peak, and end of an RSV season, study location, study period, and details in study methods were extracted. RSV seasonal patterns were examined by geographic location, calendar month, analytic method and meteorological factors including temperature and absolute humidity. Correlation and regression analyses were conducted to explore the relationship between RSV seasonality and study methods and characteristics of study locations. **Results:** RSV seasons were reported in 209 articles published in 1973-2023 for 317 locations in 77 countries. Variations were identified in types of data, data collection and analytical methods across the studies. Regular RSV seasons were similarly reported in countries in temperate regions, with highly variable seasons identified in subtropical and tropical countries. Durations of RSV seasons were relatively longer in subtropical and tropical regions than from temperate regions. Longer durations of RSV seasons were associated with a higher daily average mean temperature and daily average mean absolute humidity. Conclusions: The global seasonal patterns of RSV provided important information for optimizing interventions against RSV infection. Heterogeneity in study methods highlighted the importance of developing and applying standardized approaches in RSV surveillance and INTRODUCTION

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

Respiratory syncytial virus (RSV) is a leading cause of hospitalization for acute lower respiratory tract infection (LRTI) in young children less than 5 years old ¹⁻³, as well as an increasingly recognized important pathogen in older adults (aged \geq 65) ^{4,5}. Globally, RSV was estimated to cause nearly 25 million LRTI episodes and more than 70,000 deaths every year ⁶. In addition to Palivizumab, a monoclonal antibody recommended for high-risk infants ^{7,8} providing a short-term protection against RSV-associated severe infections ^{9,10}, a new monoclonal antibody nirsevimab with a prolonged protection ^{11,12} has been approved by the EU and the UK ¹³. Recently the first RSV vaccine (Arexvy, RSVPreF3 from GSK) approved for the use in older adults and several other vaccine candidates in their final stage of testing demonstrated promising efficacy in preventing RSV-associated LRTI and severe infections 14,15 Activities of RSV varied temporally and geographically. In temperate regions, the highest viral activities have been observed during winter months ^{16,17} with similar intensities across different years. Two-year cycles of RSV activity have been reported for some countries in Northern Europe, with a major epidemic wave in winter followed by a minor one in spring next year ¹⁸. In subtropical and tropical regions, seasonal patterns of RSV were more diverse and less clear than those reported for temperate countries ¹⁹. Knowledge about the seasonality of RSV, can guide the formulation of prevention strategies and the planning of public health resources. In particular, accurate estimates of the RSV season start and its duration can help to determine the optimal timing of initial doses and optimal dosing interval for prophylactic monoclonal antibodies and vaccination schedules.

69 We conducted a systematic review on RSV seasonality to characterize the global patterns of 70 RSV activity by summarizing the reported start, peak and end of RSV seasons worldwide and 71 describe approaches applied in analyzing the seasonality. We aimed to provide a better 72 understanding of the seasonal patterns of RSV circulation to inform policy and decisions in 73 prevention, diagnosis, and treatment of RSV infections. 74 75 **METHODS** 76 Literature search strategy and selection criteria 77 This systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines ²⁰. We focused on studies in 78 79 which seasonal patterns of RSV were characterized by providing the time of the start, peak 80 and/or end of a season based on laboratory-confirmed RSV infection data. We searched 81 published articles from PubMed on January 17, 2023 using the combination of following 82 search items (1 and 2) in "Title/Abstract" (Figure 1): 83 1. "RSV" or "Respiratory Syncytial Virus" 84 2. "seasonality" or "season*" 85 86 Two authors (S.S. and W.Z.) performed the literature search (#1 and #2) and screened 87 retrieved articles independently. Full-text screening was conducted after title/abstract 88 screening. Two authors (S.S. and W.Z.) independently identified articles for inclusion. Any 89 disagreement in article selection and data retrieval was resolved by a third author (P.W.). 90 91 Eligible articles were studies reporting the seasonality of RSV based on monthly or weekly 92 laboratory-confirmed RSV infections collected for a specified place, i.e., a city, a province or 93 a country, for three years or longer. We excluded articles if: 1) the full text was not available

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

or not in English, 2) the analysis was based on less than three years' data, 3) the average number of reported RSV infections per year in a study was less than 50, 4) the time of the start, peak and/or end of RSV seasons was not specified in a calendar month or week. If an investigation on RSV seasonality covered the time period beyond 2019, the study period before the COVID-19 pandemic ≥ 3 years would be included in our analysis, and the RSV data collected during the pandemic would be excluded. Articles without original data analysis on RSV activities, such as reviews, commentaries, letters, were excluded, but we reviewed the references of these articles for additional studies to include for screening. Data extraction and analysis Two authors (S.S. and W.Z.) independently extracted data into a standardized data extraction form. Data fields included the timing (start, peak, and end) of an RSV season, study location (city, region or country), study period, information on study characteristics (such as the source of cases, case definitions, laboratory testing methods and analytic methods applied to determine RSV seasons). We classified the sources of study cases into outpatient, inpatient, outpatient and inpatient, case definitions into influenza-like-illness (ILI) or acute respiratory infection (ARI), severe acute respiratory infection (SARI) and acute LRTI and grouped laboratory testing methods for RSV confirmation into virus detection, antibody detection, antigen detection, and nucleic acid detection. One publication might contain several different investigations on seasonal patterns of RSV, either based on different data sources, or based on the same dataset but with different analytic methods. If more than one estimate on timing of RSV season was reported in a single publication, using different data sources or methods, all were extracted and included in our analyses. It was common that one investigation on RSV seasonality was conducted based on

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

more than one type of case source, case definition and/or testing method, and all the methodological details were extracted and documented for analyses. Analytic methods used by different studies to determine the RSV seasons were classified as qualitative methods and quantitative methods based on whether the analysis on RSV seasonality was carried out using a statistical or mathematical approach, and the quantitative methods were further divided into three groups, threshold-based, coverage-based and model-based (*Supplementary Materials*). In addition to the study-specific information, we also documented the latitude, daily average mean temperature and daily average mean relative humidity for all study locations reported in each investigation using Google Geocoding API ²¹ and R package GSOR ²²(Supplementary materials). The extracted daily average mean temperature and relative humidity data were used to derive the daily average mean absolute humidity for each location. We also extracted the geoclimatic information of each study site, and classified the investigations of RSV seasonality into three groups based on the latitude of the study sites, temperate zone (latitude > 35° or latitude < -35°), subtropical zone (23.5° < latitude \le 35° or -35° \le latitude < -23.5°) and tropical zone $(-23.5^{\circ} \le \text{latitude} \le 23.5^{\circ})$. We described the reported RSV seasons as a function of geographical location, meteorological factors and characteristics of study design, and explored potential associations using Pearson correlation analyses and Kendall's rank correlation between the duration of the season and the latitude, daily average mean temperature and daily average mean absolute humidity of study sites as well as the analytic method and climate zone. Finally, linear regression models were applied to explore the independent associations between the duration of RSV seasons and the abovementioned factors as covariates. The statistical analyses were

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

conducted using R software Version 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria). RESULTS We identified 2,510 citations from the PubMed through the keyword search and additional 19 citations from other sources. In total, 209 publications were included after screening based on the inclusion and exclusion criteria (Figure 1) and 552 investigations of RSV seasonality were identified and included in analyses. The identified studies were published between 1973 and 2023, with the majority (147/209, 70%) from 2010 onwards (Supplementary Figure 1). RSV seasonality was reported for 317 distinct study sites in 77 countries from Asia, Europe, North America, South America, Oceania and Africa (Figure 2). Most investigations (342/552, 62%) were conducted with a study period of 3-6 years (Supplementary Figure 1), with the longest one from Malaysia using surveillance data over 27 years ²³. Among the identified publications, more than half (124/209, 59%) were from temperate regions (latitude > 35° or latitude < -35°), followed by 31% (65/209) and 22% (47/209) in subtropical (23.5° < latitude $\leq 35^{\circ}$ or $-35^{\circ} \leq$ latitude < -23.5°) and tropical (-23.5° \leq latitude \leq 23.5°) regions, respectively (Table 1, Supplementary Table 1). The information on the case source, case definition, and laboratory testing methods was missing in some investigations (case source: 260/552, 47%; case definition: 310/552, 56%; testing method: 127/552, 23%). Among those with information of case source and case definition provided, the majority of investigations (152/292, 52%) identified RSV cases from inpatients, and ARI or ILI (150/242, 62%) was the most frequently used syndromic

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

definitions to screen patients for RSV testing, and antigen (325/552, 59%) and nucleic acid detections (323/552, 59%) were the most commonly used laboratory testing methods in more recent publications (Table 1, Supplementary Table 1, Supplementary Figures 2-3). The majority of investigations (373/552, 68%) applied quantitative methods to determine the time of the start, peak and/or end of seasons, and among these studies, over half of the investigations used the threshold-based method (205/373, 55%) (Supplementary Tables 2-3). The majority of the investigations were conducted using data collected from locations in the Northern Hemisphere (NH) and indicated one RSV season every year (Figure 2). A small number of investigations (11/552, 2%) reported two RSV peaks identified in one year (Supplementary Table 4) while 18 (3%) investigations indicated unique RSV seasonal patterns repeated every 2 years (Supplementary Table 5). Among study sites reporting one RSV season annually, locations in temperate countries were fairly consistent in the time of the start, peak and end of RSV seasons in either the NH or Southern Hemisphere (SH) (Figure 3). In temperate countries, RSV activities generally started from late autumn or early winter, i.e., October-December in NH, May-June in SH, peaked in winter (December-February in NH, and June to July in SH), and ended in late winter or spring (February-May in NH, and July-September in SH). (Figure 3, Supplementary Figure 4). Larger variations were observed in the start, peak and end month of RSV seasons in subtropical and tropical countries at a lower latitude, with high RSV activities observed in July/August-November in tropical locations (Supplementary Figures 5-6). The durations of RSV seasons were relatively shorter in study sites in the temperate region (median: 3.97 months, interquartile range (IQR): 3.00-5.00) compared with the estimates from subtropical (4.00, 3.52-6.14) and tropical countries (5.00, 4.00-6.00) (Figure 2, Supplementary Figure 6).

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

The Pearson correlation analysis indicated an overall negative association between the duration of the RSV season (in months) and the latitude both in the NH (p<0.001) and the SH (p=0.002) (Supplementary Table 7), and the statistical significance in the association was only indicated with the estimates derived from quantitative methods (p<0.001). Positive associations were indicated in the correlation analyses between the daily average mean temperature (correlation coefficient: 0.33; 95% CI: 0.22, 0.44) and absolute humidity (0.34; 0.22, 0.45) of the study locations and the durations of RSV season estimated by the quantitative methods (p<0.001) but not for those estimated by the qualitative methods (Supplementary Table 7). Durations of RSV seasons appeared to be longer in tropical subtropical regions than the estimates from temperate regions, and the estimated RSV seasons were longer from the threshold-based methods, but shorter from the coverage-based method (Table 2, Supplementary Table 8). In the main analysis with the linear regression model, we identified that climatic zone appeared to be independently associated with the estimated duration of RSV seasons, and analytic method used in estimating RSV seasons, annual daily average mean absolute humidity at the study location could also explain some variations (Adjusted R²=0.33 for estimates from quantitative approaches, 0.25 for all estimates) in the estimated durations of RSV seasons (Table 2, Supplementary Table 8). Considering the close intercorrelations between climatic zone, latitude and temperature, we included the climatic zone (Table 2, Supplementary Table 8), latitude (Supplementary Tables 9-10) and daily average mean temperature (Supplementary Tables 11-12) of study locations into different linear regression models separately. The duration of RSV season would decrease by 0.041 (95% CI: 0.017, 0.064) months with every increase of 1 degree in latitude, and increase by 0.058 (95%CI: 0.0077, 0.11) months with every increase of 1 degree in daily average mean temperature.

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

Durations of RSV seasons estimated for the subtropical and tropical locations were on average 1.06 (95% CI: 0.45, 1.66) and 1.65 (95% CI: 0.77, 2.54) months longer than for the study sites in the temperate region. Compared to the coverage-based methods, the thresholdbased methods tended to produce longer estimates of the duration of RSV season by 1.43 (95% CI: 0.96, 1.90) months. Overall, the duration of RSV season prolonged by 0.013 (95% CI: -0.0048, 0.030) months with every 1 g/m³ increase in absolute humidity at the study location (Table 2). **DISCUSSION** RSV seasonal patterns have been studied widely in particular since the last decade, with most of the data reported from temperate countries in the Northern Hemisphere. Our review indicated that largely similar seasonal patterns of RSV were observed in locations from the same climatic region either in the NH or the SH. In temperate regions, RSV activities primarily showed regular annual patterns starting in winter seasons, and the estimated durations of RSV season were relatively shorter than the reported from tropical and subtropical regions where prolonged RSV circulations were often more than half a year with greatly varied times of season start and/or peak. Human infections of RSV are likely driven by two major antigenic groups, A and B 24 between which cross-immunity has been suggested ^{25,26}. However, RSV typing is often not included in most of the established surveillance systems ²⁷. The increasing susceptibility in infants due to the loss of protection from waning maternal antibodies leads to a higher risk of infection particularly in young children with high-risk conditions ^{1,28,29}, potentially driving the transmission of RSV in the population ³⁰ although the virus can infect people at any age including older adults ^{31,32}. RSV shows comparable environmental survivability and

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

transmissibility to influenza viruses with a similar estimate of the basic reproduction number (R₀) and household second attack rate ³³. Increasing RSV activities were commonly reported in cold seasons starting from late autumn through to early spring in temperate regions, and in rainy seasons in tropical/subtropical areas, and the associations between RSV activities and environmental factors including temperature, relative/absolute humidity, rainfall were inconsistently reported from studies conducted in tropical areas ³⁴⁻³⁶. RSV seasonality characterised in different studies appeared to be associated with the approaches used in data collection and analysis ¹⁹. Previous research demonstrated that the timing of RSV seasons determined with laboratory surveillance data might be different from the results based on hospitalized patient data although the two estimates were highly correlated ³⁷. The improvement of laboratory testing methods could also affect the estimates of RSV seasons ^{38,39}. Our review showed that estimates of the timing of RSV seasons were correlated with the analytic approaches used in the studies, with shorter durations of RSV seasons estimated from "coverage-based method" (defined as the shortest time period when the majority of confirmed (severe) RSV infections occurred) than the estimates from the threshold-based methods which although were highly dependent on the often arbitrarily selected threshold of varied measures for RSV activities, such as proportion of virus detections or patients presenting ILI/ARI symptoms 40. Therefore, prudent comparison and interpretation of RSV seasons estimated from different studies or with different approaches is necessary. RSV surveillance is often established based on the existing routine surveillance on influenza, more commonly seen in developed economies including the US 41, Canada 42 and some European countries ⁴³. The WHO initiated a pilot RSV surveillance scheme by leveraging the

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

current Global Influenza Surveillance and Response System covering over 100 countries to explore possible surveillance strategies including case definitions, laboratory methods and target population, etc. 44. Current RSV surveillance largely applied similar syndromic case definitions as those used for influenza surveillance, i.e., sampling patients showing influenzalike-illness and testing for the virus, while the validity of using such case definitions for RSV surveillance has been questioned 45. In some countries/areas RSV surveillance was not conducted throughout a year but only during restricted period(s) following the influenza surveillance protocol given the regular annual influenza seasons in those locations ^{17,46}. However, this might lead to an underreporting of RSV infections during the non-surveillance periods ⁴⁷. During the COVID-19 pandemic, circulation of respiratory viruses including RSV changed considerably worldwide largely due to implementation of non-pharmaceutical interventions and changes in human behaviours in response to the pandemic ^{48,49}. RSV remained at a low level in many countries in 2020 when public health and social measure were widely adopted globally to contain the spread of SARS-CoV-2, but caused surges of infections with a large number of severe cases admitted into hospital in some countries when some interventions were relaxed from 2021 onwards ^{50,51}, including the US during 2021-2023 ⁵², some geographically separated locations in Australia in 2020-21 53 and the UK in 2021-22 54. The inter-seasonal viral activities were perhaps related to the increased susceptibility in the population due to the lack of exposure to RSV during the previous year in response to COVID-19 55. Monoclonal antibodies approved for prophylactic therapy provide immediate protection of high-risk individuals particularly young children against RSV-associated severe infections ^{7,13}.

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

Five monthly injections of palivizumab and a single dose of nirsevimab can substantially reduce the risk of hospitalizations due to RSV in individuals receiving the therapy throughout RSV seasons especially in temperate regions where RSV seasons would normally not be longer than 5 months. The duration of protection provided by RSV vaccines has not been fully determined although promising efficacy for short-term prevention from infections was demonstrated in clinical trials ⁵⁶⁻⁵⁸. The effectiveness of the abovementioned pharmaceutical interventions for high-risk population is determined by the duration of protection of the monoclonal antibodies and the vaccines, the timing of administration and RSV activities in specific locations. Ideally these preventive measures should be administered before an RSV season starts, and the protection can maintain throughout the season, likely during November - April, and May - October in temperate regions of the NH and the SH, respectively. However great challenges in implementing these efficacious interventions would be seen in locations where there were irregular seasons particularly with prolonged viral circulations ⁵⁹⁻ ⁶¹. Based on the reported seasonal patterns in locations from northern temperate regions in this review, the Studies incorporating epidemiologic analysis on RSV seasonality into the effectiveness and cost-effectiveness of these RSV preventive strategies are urgently needed ⁶². There are several limitations in this study. First, data of RSV seasonality that were published and included in the review were skewed to high-income countries with well-established RSV surveillance systems. These countries are largely in temperate regions where RSV circulation might be different from the underrepresented middle- and low-income countries due to varied population structure, contact patterns and geoclimatic features ⁶³. Second, RSV antigenic information could not be incorporated into the current analysis of seasonality due to the lack of data. Expanding RSV surveillance by collecting antigenic and genetic data is urgently needed to improve our understanding of the transmission dynamics of RSV locally and

globally ⁶⁴. Third, except for the analytic method, we could not examine potential associations between RSV seasonality and other study characteristics such as case sources, case definitions, and laboratory methods due to the lack of information and non-standardized laboratory protocols used for RSV surveillance, or explore the association between RSV seasonality and population structure particularly birth rate given the lack of data although a high disease burden of RSV identified in young children ⁶⁵⁻⁶⁷ implied a possible driving force from the young population on RSV activities. Lastly, the reported data of seasonality in this review did not allow us to investigate the RSV-associated disease burden occurred during the characterised RSV seasons which is a critical metric for evaluation of the health impact related to RSV circulation, particularly when there were large uncertainties in the start and the end of RSV seasons in a specific location and the infection risk is less likely to be homogeneous in a population over the season.

CONCLUSIONS

This study provided a global overview of RSV seasonality before the COVID-19 pandemic.

The seasonal patterns illustrated in this review may inform optimal use of preventive and

therapeutic interventions against RSV infection particularly in temperate regions of the NH

and SH. Considerable variations in methods used by different studies highlighted the

importance of developing and applying standardized approaches in RSV surveillance and

data reporting. Further research is needed to understand the underlying mechanisms driving

RSV seasonal patterns locally and globally.

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

ACKNOWLEDGEMENTS The authors thank Prof. Julian W Tang, and Dr. Eeva Broberg for kindly sharing the data of RSV seasonality from their publications. The authors also thank Stella SW Lai for technical assistance. **FUNDING** This project was supported by the Health and Medical Research Fund (project no. 19200861) from Food Bureau of Hong Kong SAR Government, and the AIR@InnoHK administered by the Innovation and Technology Commission of Hong Kong SAR Government. The funding bodies had no role in study design, data collection and analysis, preparation of the manuscript, or the decision to publish. **AUTHOR CONTRIBUTIONS** All authors meet the International Committee of Medical Journal Editors criteria for authorship. SS, PW, BY, DZ conceived and designed the study; SS, WZ, HG, PH collected and extracted data; SS, PW conducted the data analysis and wrote the first draft of the manuscript. All authors contributed to the interpretation of the results and revision of the manuscript, and have approved the final version of the manuscript. **DECLATATION OF INTERESTS** JN was previously employed by and owns shares in Sanofi. The authors report no other potential conflicts of interest.

REFERENCES

364

- 1. Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of
- 367 acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in
- 368 2019: a systematic analysis. *Lancet* 2022; **399**(10340): 2047-64.
- Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due
- 370 to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010;
- **371 375**(9725): 1545-55.
- 372 3. Shi T, McLean K, Campbell H, Nair H. Aetiological role of common respiratory viruses in
- acute lower respiratory infections in children under five years: A systematic review and meta-analysis.
- 374 *J Glob Health* 2015; **5**(1): 122-31.
- 4. Falsey AR, McElhaney JE, Beran J, et al. Respiratory syncytial virus and other respiratory
- viral infections in older adults with moderate to severe influenza-like illness. J Infect Dis 2014;
- **209**(12): 1873-81.
- 5. Falsey AR, Walsh EE. Respiratory syncytial virus infection in elderly adults. *Drugs Aging*
- 379 2005; **22**(7): 577-87.
- 380 6. Troeger C, Forouzanfar M, Rao PC, et al. Estimates of the global, regional, and national
- 381 morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a
- 382 systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis 2017; 17(11):
- 383 1133-61.
- 384 7. Brady MT, Byington CL, Davies HD, et al. Updated Guidance for Palivizumab Prophylaxis
- 385 Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial
- 386 Virus Infection. *Pediatrics* 2014; **134**(2): E620-E38.
- 8. Reeves RM, van Wijhe M, Lehtonen T, et al. A Systematic Review of European Clinical
- Practice Guidelines for Respiratory Syncytial Virus Prophylaxis. J Infect Dis 2022; **226**(Suppl 1):
- 389 S110-S6.
- 390 9. Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for Prevention of RSV in Healthy Late-
- 391 Preterm and Term Infants. *N Engl J Med* 2022; **386**(9): 837-46.

- 392 10. Simoes EAF, Madhi SA, Muller WJ, et al. Efficacy of nirsevimab against respiratory
- 393 syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic
- 394 extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of
- randomised controlled trials. *Lancet Child Adolesc Health* 2023; **7**(3): 180-9.
- 396 11. Garegnani L, Styrmisdottir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco
- 397 JV. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.
- 398 *Cochrane Database Syst Rev* 2021; **11**(11): CD013757.
- 399 12. Null D, Bimle C, Weisman L, et al. Palivizumab, a humanized respiratory syncytial virus
- 400 monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk
- 401 infants. *Pediatrics* 1998; **102**(3): 531-7.
- 402 13. Keam SJ. Nirsevimab: First Approval. *Drugs* 2023; **83**(2): 181-7.
- 403 14. Mazur NI, Terstappen J, Baral R, et al. Respiratory syncytial virus prevention within reach:
- the vaccine and monoclonal antibody landscape. *Lancet Infect Dis* 2023; **23**(1): E2-E21.
- 405 15. Valero MV. Green light from US regulatory agency for GSK's jab caps off a decades-long
- 406 quest. 2023. https://www.nature.com/articles/d41586-023-01529-5 (accessed May 6 2023).
- 407 16. Li Y, Reeves RM, Wang X, et al. Global patterns in monthly activity of influenza virus,
- 408 respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. Lancet
- 409 *Glob Health* 2019; **7**(8): e1031-e45.
- 410 17. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, et al. Respiratory Syncytial Virus
- 411 Seasonality: A Global Overview. *J Infect Dis* 2018; **217**(9): 1356-64.
- 412 18. Broberg EK, Waris M, Johansen K, Snacken R, Penttinen P, European Influenza Surveillance
- 413 N. Seasonality and geographical spread of respiratory syncytial virus epidemics in 15 European
- 414 countries, 2010 to 2016. Euro Surveill 2018; **23**(5).
- 415 19. Staadegaard L, Caini S, Wangchuk S, et al. Defining the seasonality of respiratory syncytial
- 416 virus around the world: National and subnational surveillance data from 12 countries. *Influenza Other*
- 417 *Respir Viruses* 2021; **15**(6): 732-41.
- 418 20. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and
- meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4(1): 1.

- 420 21. Geocoding API. https://developers.google.com/maps/documentation/geocoding.
- 421 22. GSODR: Global Surface Summary of the Day ('GSOD') Weather Data Client. https://cran.r-
- 422 project.org/web/packages/GSODR/index.html.
- 423 23. Khor CS, Sam IC, Hooi PS, Quek KF, Chan YF. Epidemiology and seasonality of respiratory
- viral infections in hospitalized children in Kuala Lumpur, Malaysia: a retrospective study of 27 years.
- 425 *Bmc Pediatr* 2012; **12**.
- 426 24. Sullender WM. Respiratory syncytial virus genetic and antigenic diversity. Clin Microbiol
- 427 *Rev* 2000; **13**(1): 1-15, table of contents.
- 428 25. Bhattacharyya S, Gesteland PH, Korgenski K, Bjornstad ON, Adler FR. Cross-immunity
- between strains explains the dynamical pattern of paramyxoviruses. P Natl Acad Sci USA 2015;
- 430 **112**(43): 13396-400.
- White LJ, Waris M, Cane PA, Nokes DJ, Medley GF. The transmission dynamics of groups
- 432 A and B human respiratory syncytial virus (hRSV) in England & Wales and Finland: seasonality and
- 433 cross-protection. *Epidemiol Infect* 2005; **133**(2): 279-89.
- 434 27. Chadha M, Hirve S, Bancej C, et al. Human respiratory syncytial virus and influenza
- seasonality patterns-Early findings from the WHO global respiratory syncytial virus surveillance.
- 436 *Influenza Other Resp* 2020; **14**(6): 638-46.
- 437 28. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection
- 438 in young children. *N Engl J Med* 2009; **360**(6): 588-98.
- 439 29. Meissner HC. Selected populations at increased risk from respiratory syncytial virus infection.
- 440 *Pediatr Infect Dis J* 2003; **22**(2): S40-S5.
- 441 30. Hogan AB, Glass K, Moore HC, Anderssen RS. Exploring the dynamics of respiratory
- 442 syncytial virus (RSV) transmission in children. *Theor Popul Biol* 2016; **110**: 78-85.
- 443 31. Savic M, Penders Y, Shi T, Branche A, Pircon JY. Respiratory syncytial virus disease burden
- in adults aged 60 years and older in high-income countries: A systematic literature review and meta-
- analysis. *Influenza Other Resp* 2023; **17**(1).

- 446 32. Shi T, Denouel A, Tietjen AK, et al. Global Disease Burden Estimates of Respiratory
- 447 Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic
- 448 Review and Meta-Analysis. *J Infect Dis* 2020; **222**: S577-S83.
- 449 33. Leung NHL. Transmissibility and transmission of respiratory viruses. Nat Rev Microbiol
- 450 2021; **19**(8): 528-45.
- 451 34. Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of Respiratory Viral Infections. Annu
- 452 Rev Virol 2020; 7: 83-101.
- 453 35. Paynter S. Humidity and respiratory virus transmission in tropical and temperate settings.
- 454 Epidemiol Infect 2015; **143**(6): 1110-8.
- 455 36. Tang JLW, Loh TP. Correlations between climate factors and incidence-a contributor to RSV
- 456 seasonality. Rev Med Virol 2014; **24**(1): 15-34.
- 457 37. Hampp C, Asal N, Lipowski E, et al. Validity of Laboratory-based Surveillance for Detection
- of Respiratory Syncytial Virus Seasons. *Am J Epidemiol* 2013; **177**(8): 841-51.
- 459 38. Ambrose CS, Steed LL, Brandon M, Frye K, Olajide IR, Thomson G. National and regional
- 460 modeling of distinct RSV seasonality thresholds for antigen and PCR testing in the United States. J
- 461 *Clin Virol* 2019; **120**: 68-77.
- 462 39. Midgley CM, Haynes AK, Baumgardner JL, et al. Determining the Seasonality of Respiratory
- Syncytial Virus in the United States: The Impact of Increased Molecular Testing. *J Infect Dis* 2017;
- 464 **216**(3): 345-55.
- 465 40. Rose EB, Wheatley A, Langley G, Gerber S, Haynes A. Respiratory Syncytial Virus
- 466 Seasonality United States, 2014-2017. *Mmwr-Morbid Mortal W* 2018; **67**(2): 71-6.
- 467 41. National Respiratory and Enteric Virus Surveillance System.
- 468 https://www.cdc.gov/surveillance/nrevss/index.html.
- 469 42. Flu (influenza): FluWatch surveillance Canada.ca. https://www.canada.ca/en/public-
- 470 health/services/diseases/flu-influenza/influenza-surveillance.html.
- 471 43. Surveillance Atlas of Infectious Diseases. https://atlas.ecdc.europa.eu/public/index.aspx.

- 472 44. Broor S, Campbell H, Hirve S, et al. Leveraging the Global Influenza Surveillance and
- 473 Response System for global respiratory syncytial virus surveillance-opportunities and challenges.
- 474 Influenza Other Resp 2020; **14**(6): 622-9.
- 475 45. Hirve S, Crawford N, Palekar R, Zhang WQ, Grp WRS. Clinical characteristics, predictors,
- and performance of case definition-Interim results from the WHO global respiratory syncytial virus
- 477 surveillance pilot. *Influenza Other Resp* 2020; **14**(6): 647-57.
- 478 46. Teirlinck AC, Broberg EK, Berg AS, et al. Recommendations for respiratory syncytial virus
- 479 surveillance at the national level. *Eur Respir J* 2021; **58**(3).
- 480 47. Mollers M, Barnadas C, Broberg EK, et al. Current practices for respiratory syncytial virus
- 481 surveillance across the EU/EEA Member States, 2017. Euro Surveill 2019; 24(40).
- 482 48. Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-
- 483 19 nonpharmaceutical interventions on the future dynamics of endemic infections. *Proc Natl Acad Sci*
- 484 *USA* 2020; **117**(48): 30547-53.
- 485 49. Oh DY, Buda S, Biere B, et al. Trends in respiratory virus circulation following COVID-19-
- 486 targeted nonpharmaceutical interventions in Germany, January September 2020: Analysis of
- national surveillance data. *Lancet Reg Health Eur* 2021; **6**: 100112.
- 488 50. Bozzola E, Barni S, Villani A. Respiratory Syncytial Virus Pediatric Hospitalization in the
- 489 COVID-19 Era. Int J Environ Res Public Health 2022; 19(23).
- 490 51. Fairbank R. RSV wave hammers hospitals but vaccines and treatments are coming. *Nature*
- 491 2022.
- 492 52. Lindsey Wang PBD, Nathan A Berger, David C Kaelber, Nora D Volkow, Rong Xu.
- Disruption in seasonality, patient characteristics and disparities of respiratory syncytial virus infection
- among young children in the US during and before the COVID-19 pandemic: 2010-2022. medRxiv;
- 495 2022.
- 496 53. Eden JS, Sikazwe C, Xie RP, et al. Off-season RSV epidemics in Australia after easing of
- 497 COVID-19 restrictions. *Nat Commun* 2022; **13**(1).
- 498 54. Bardsley M, Morbey RA, Hughes HE, et al. Epidemiology of respiratory syncytial virus in
- 499 children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory,

- 500 clinical, and syndromic surveillance: a retrospective observational study. Lancet Infect Dis 2023;
- **23**(1): 56-66.
- 502 55. Garg I, Shekhar R, Sheikh A, Pal S. Impact of COVID-19 on the Changing Patterns of
- Respiratory Syncytial Virus Infections. *Infect Dis Rep* 2022; **14**(4): 558-68.
- 504 56. Falsey AR, Williams K, Gymnopoulou E, et al. Efficacy and Safety of an Ad26.RSV.preF-
- RSV preF Protein Vaccine in Older Adults. N Engl J Med 2023; 388(7): 609-20.
- 506 57. Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to
- 507 Prevent RSV Illness in Infants. *N Engl J Med* 2023; **388**(16): 1451-64.
- 508 58. Walsh EE, Perez Marc G, Zareba AM, et al. Efficacy and Safety of a Bivalent RSV Prefusion
- 509 F Vaccine in Older Adults. *N Engl J Med* 2023; **388**(16): 1465-77.
- 510 59. Bauman J, Eggleston M, Oquist N, Malinoski F. Respiratory syncytial virus: Seasonal data
- for regions of Florida and implications for palivizumab. *South Med J* 2007; **100**(7): 669-76.
- 512 60. Hsu CH, Lin CY, Chi H, et al. Prolonged Seasonality of Respiratory Syncytial Virus Infection
- among Preterm Infants in a Subtropical Climate. *Plos One* 2014; **9**(10).
- 514 61. Janet S, Broad J, Snape MD. Respiratory syncytial virus seasonality and its implications on
- prevention strategies. *Hum Vacc Immunother* 2018; **14**(1): 234-44.
- 516 62. Getaneh AM, Li X, Mao Z, et al. Cost-effectiveness of monoclonal antibody and maternal
- 517 immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European
- 518 countries. *Vaccine* 2023; **41**(9): 1623-31.
- 519 63. Tang JW, Lam TT, Zaraket H, et al. Global epidemiology of non-influenza RNA respiratory
- 520 viruses: data gaps and a growing need for surveillance. *Lancet Infect Dis* 2017; **17**(10): E320-E6.
- 521 64. Staadegaard L, Meijer A, Rodrigues AP, et al. Temporal Variations in Respiratory Syncytial
- Virus Epidemics, by Virus Subtype, 4 Countries. *Emerg Infect Dis* 2021; **27**(5): 1537-40.
- 523 65. Glatman-Freedman A, Kaufman Z, Applbaum Y, et al. Respiratory Syncytial Virus
- 524 hospitalization burden: a nation-wide population-based analysis, 2000-2017. J Infect 2020; 81(2):
- 525 297-303.

- 526 66. Johannesen CK, van Wijhe M, Tong S, et al. Age-Specific Estimates of Respiratory Syncytial
- 527 Virus-Associated Hospitalizations in 6 European Countries: A Time Series Analysis. J Infect Dis
- 528 2022; **226**(Suppl 1): S29-S37.

- 529 67. Tong S, Amand C, Kieffer A, Kyaw MH. Incidence of respiratory syncytial virus related
- health care utilization in the United States. *J Glob Health* 2020; **10**(2): 020422.

Table 1. Characteristics of publications and investigations included in the systematic review.

Climatic zone Temperate (>35°) 123 (58·9) 335 (60·7) Subtropical (23·5° - 35°) 65 (31·1) 134 (24·3) Tropical (equator - 23·5°) 49 (23·4) 83 (15·0) Continent	Characteristics	No. of Publications (N=209) ^a n (%)	No. of Investigations (N = 552) n (%)	
Subtropical (23·5° - 35°) 65 (31·1) 134 (24·3) Tropical (equator - 23·5°) 49 (23·4) 83 (15·0) Continent 83 (15·0) Asia 64 (30·6) 140 (25·4) Europe 68 (32·5) 155 (28·1) North America 38 (18·2) 164 (29·7) South America 14 (6·7) 49 (8·9) Africa 12 (5·7) 24 (4·3) Oceania 5 (2·4) 19 (3·4) Others b 8 (3·8) 1 (0·2) Study period ° Before Palivizumab approved 75 (35·9) 320 (58·0) Others d 46 (22·0) 85 (15·4) Length of study period 3-6 years 127 (60·8) 342 (62·0) 7-10 years 53 (25·4) 123 (22·3) > 10 years 37 (17·7) 87 (15·8) Type of RSV data Weekly data 57 (27·3) 294 (53·3) Monthly data 155 (74·2) 258 (46·7) Analytic method Qualitative 146 (69·9) 179 (32·4)	Climatic zone			
Tropical (equator - 23.5°) Continent Asia 64 (30.6) 140 (25.4) Europe 68 (32.5) 155 (28.1) North America 38 (18.2) 164 (29.7) South America 14 (6-7) 49 (8.9) Africa 12 (5.7) 24 (4.3) Oceania 5 (2.4) 19 (3.4) Others b 8 (3.8) 1 (0.2) Study period c Before Palivizumab approved 88 (42.1) 147 (26.6) After Palivizumab approved 75 (35.9) 320 (58.0) Others d 46 (22.0) 85 (15.4) Length of study period 3-6 years 127 (60.8) 342 (62.0) 7-10 years 53 (25.4) 123 (22.3) > 10 years 37 (17.7) 87 (15.8) Type of RSV data Weekly data 57 (27.3) 294 (53.3) Monthly data 155 (74.2) 258 (46.7) Analytic method Qualitative 146 (69.9) 179 (32.4)	Temperate (>35°)	123 (58-9)	335 (60·7)	
Asia 64 (30-6) 140 (25-4) Europe 68 (32-5) 155 (28-1) North America 38 (18-2) 164 (29-7) South America 14 (6-7) 49 (8-9) Africa 12 (5-7) 24 (4-3) Oceania 5 (2-4) 19 (3-4) Others b 8 (3-8) 1 (0-2) Study period c Before Palivizumab approved 88 (42-1) 147 (26-6) After Palivizumab approved 75 (35-9) 320 (58-0) Others d 46 (22-0) 85 (15-4) Length of study period 3-6 years 127 (60-8) 342 (62-0) 7-10 years 53 (25-4) 123 (22-3) > 10 years 37 (17-7) 87 (15-8) Type of RSV data Weekly data 57 (27-3) 294 (53-3) Monthly data 155 (74-2) 258 (46-7) Analytic method Qualitative 146 (69-9) 179 (32-4)	Subtropical (23·5° - 35°)	65 (31·1)	134 (24·3)	
Asia 64 (30-6) 140 (25-4) Europe 68 (32-5) 155 (28-1) North America 38 (18-2) 164 (29-7) South America 14 (6-7) 49 (8-9) Africa 12 (5-7) 24 (4-3) Oceania 5 (2-4) 19 (3-4) Others b 8 (3-8) 1 (0-2) Study period c Before Palivizumab approved 88 (42-1) 147 (26-6) After Palivizumab approved 75 (35-9) 320 (58-0) Others d 46 (22-0) 85 (15-4) Length of study period 3-6 years 127 (60-8) 342 (62-0) 7-10 years 53 (25-4) 123 (22-3) > 10 years 37 (17-7) 87 (15-8) Type of RSV data Weekly data 57 (27-3) 294 (53-3) Monthly data 155 (74-2) 258 (46-7) Analytic method Qualitative 146 (69-9) 179 (32-4)	Tropical (equator - 23·5°)	49 (23.4)	83 (15.0)	
Europe 68 (32-5) 155 (28-1) North America 38 (18-2) 164 (29-7) South America 14 (6-7) 49 (8-9) Africa 12 (5-7) 24 (4-3) Oceania 5 (2-4) 19 (3-4) Others b 8 (3-8) 1 (0-2) Study period c Before Palivizumab approved 88 (42-1) 147 (26-6) After Palivizumab approved 75 (35-9) 320 (58-0) Others d 46 (22-0) 85 (15-4) Length of study period 3-6 years 127 (60-8) 342 (62-0) 7-10 years 53 (25-4) 123 (22-3) > 10 years 37 (17-7) 87 (15-8) Type of RSV data Weekly data 57 (27-3) 294 (53-3) Monthly data 155 (74-2) 258 (46-7) Analytic method Qualitative 146 (69-9) 179 (32-4)	Continent			
North America 38 (18·2) 164 (29·7) South America 14 (6·7) 49 (8·9) Africa 12 (5·7) 24 (4·3) Oceania 5 (2·4) 19 (3·4) Others b 8 (3·8) 1 (0·2) Study period c Before Palivizumab approved 88 (42·1) 147 (26·6) After Palivizumab approved 75 (35·9) 320 (58·0) Others d 46 (22·0) 85 (15·4) Length of study period 3-6 years 127 (60·8) 342 (62·0) 7-10 years 53 (25·4) 123 (22·3) > 10 years 37 (17·7) 87 (15·8) Type of RSV data Weekly data 57 (27·3) 294 (53·3) Monthly data 155 (74·2) 258 (46·7) Analytic method Qualitative 146 (69·9) 179 (32·4)	Asia	64 (30·6)	140 (25.4)	
South America 14 (6-7) 49 (8-9) Africa 12 (5-7) 24 (4-3) Oceania 5 (2-4) 19 (3-4) Others 8 (3-8) 1 (0-2) Study period Before Palivizumab approved 88 (42-1) 147 (26-6) After Palivizumab approved 75 (35-9) 320 (58-0) Others d 46 (22-0) 85 (15-4) Length of study period 3-6 years 127 (60-8) 342 (62-0) 7-10 years 53 (25-4) 123 (22-3) > 10 years 37 (17-7) 87 (15-8) Type of RSV data Weekly data 57 (27-3) 294 (53-3) Monthly data 155 (74-2) 258 (46-7) Analytic method Qualitative 146 (69-9) 179 (32-4)	Europe	68 (32·5)	155 (28·1)	
Africa 12 (5·7) 24 (4·3) Oceania 5 (2·4) 19 (3·4) Others b 8 (3·8) 1 (0·2) Study period c Before Palivizumab approved 88 (42·1) 147 (26·6) After Palivizumab approved 75 (35·9) 320 (58·0) Others d 46 (22·0) 85 (15·4) Length of study period 3-6 years 127 (60·8) 342 (62·0) 7-10 years 53 (25·4) 123 (22·3) > 10 years 37 (17·7) 87 (15·8) Type of RSV data Weekly data 57 (27·3) 294 (53·3) Monthly data 155 (74·2) 258 (46·7) Analytic method Qualitative 146 (69·9) 179 (32·4)	North America	38 (18·2)	164 (29·7)	
Oceania 5 (2-4) 19 (3-4) Others b 8 (3-8) 1 (0-2) Study period c Before Palivizumab approved 88 (42-1) 147 (26-6) After Palivizumab approved 75 (35-9) 320 (58-0) Others d 46 (22-0) 85 (15-4) Length of study period 3-6 years 127 (60-8) 342 (62-0) 7-10 years 53 (25-4) 123 (22-3) > 10 years 37 (17-7) 87 (15-8) Type of RSV data Weekly data 57 (27-3) 294 (53-3) Monthly data 155 (74-2) 258 (46-7) Analytic method Qualitative 146 (69-9) 179 (32-4)	South America	14 (6.7)	49 (8.9)	
Others b 8 (3.8) 1 (0.2) Study period c Before Palivizumab approved 88 (42·1) 147 (26·6) After Palivizumab approved 75 (35·9) 320 (58·0) Others d 46 (22·0) 85 (15·4) Length of study period 3-6 years 127 (60·8) 342 (62·0) 7-10 years 53 (25·4) 123 (22·3) > 10 years 37 (17·7) 87 (15·8) Type of RSV data Weekly data 57 (27·3) 294 (53·3) Monthly data 155 (74·2) 258 (46·7) Analytic method Qualitative 146 (69·9) 179 (32·4)	Africa	12 (5.7)	24 (4·3)	
Study period ° Before Palivizumab approved 88 (42·1) 147 (26·6) After Palivizumab approved 75 (35·9) 320 (58·0) Others d 46 (22·0) 85 (15·4) Length of study period 127 (60·8) 342 (62·0) 7-10 years 53 (25·4) 123 (22·3) > 10 years 37 (17·7) 87 (15·8) Type of RSV data Weekly data 57 (27·3) 294 (53·3) Monthly data 155 (74·2) 258 (46·7) Analytic method Qualitative 146 (69·9) 179 (32·4)	Oceania	5 (2.4)	19 (3.4)	
Before Palivizumab approved 88 (42·1) 147 (26·6) After Palivizumab approved 75 (35·9) 320 (58·0) Others d 46 (22·0) 85 (15·4) Length of study period 3-6 years 127 (60·8) 342 (62·0) 7-10 years 53 (25·4) 123 (22·3) > 10 years 37 (17·7) 87 (15·8) Type of RSV data Weekly data 57 (27·3) 294 (53·3) Monthly data 155 (74·2) 258 (46·7) Analytic method Qualitative 146 (69·9) 179 (32·4)	Others b	8 (3.8)	1 (0.2)	
After Palivizumab approved 75 (35.9) 320 (58.0) Others ^d 46 (22.0) 85 (15.4) Length of study period 3-6 years 127 (60.8) 342 (62.0) 7-10 years 53 (25.4) 123 (22.3) > 10 years 37 (17.7) 87 (15.8) Type of RSV data Weekly data 57 (27.3) 294 (53.3) Monthly data 155 (74.2) 258 (46.7) Analytic method Qualitative 146 (69.9) 179 (32.4)	Study period ^c			
Others ^d 46 (22·0) 85 (15·4) Length of study period 3-6 years 127 (60·8) 342 (62·0) 7-10 years 53 (25·4) 123 (22·3) > 10 years 37 (17·7) 87 (15·8) Type of RSV data Weekly data 57 (27·3) 294 (53·3) Monthly data 155 (74·2) 258 (46·7) Analytic method Qualitative 146 (69·9) 179 (32·4)	Before Palivizumab approved	88 (42·1)	147 (26-6)	
Length of study period 3-6 years 127 (60·8) 342 (62·0) 7-10 years 53 (25·4) 123 (22·3) > 10 years 37 (17·7) 87 (15·8) Type of RSV data Weekly data 57 (27·3) 294 (53·3) Monthly data 155 (74·2) 258 (46·7) Analytic method Qualitative 146 (69·9) 179 (32·4)	After Palivizumab approved	75 (35.9)	320 (58·0)	
3-6 years 127 (60·8) 342 (62·0) 7-10 years 53 (25·4) 123 (22·3) > 10 years 37 (17·7) 87 (15·8) Type of RSV data Weekly data 57 (27·3) 294 (53·3) Monthly data 155 (74·2) 258 (46·7) Analytic method Qualitative 146 (69·9) 179 (32·4)	Others ^d	46 (22·0)	85 (15.4)	
7-10 years 53 (25·4) 123 (22·3) > 10 years 37 (17·7) 87 (15·8) Type of RSV data Weekly data 57 (27·3) 294 (53·3) Monthly data 155 (74·2) 258 (46·7) Analytic method Qualitative 146 (69·9) 179 (32·4)	Length of study period			
> 10 years 37 (17·7) 87 (15·8) Type of RSV data Weekly data 57 (27·3) 294 (53·3) Monthly data 155 (74·2) 258 (46·7) Analytic method Qualitative 146 (69·9) 179 (32·4)	3-6 years	127 (60·8)	342 (62·0)	
Type of RSV data Weekly data 57 (27·3) 294 (53·3) Monthly data 155 (74·2) 258 (46·7) Analytic method Qualitative 146 (69·9) 179 (32·4)	7-10 years	53 (25.4)	123 (22.3)	
Weekly data 57 (27·3) 294 (53·3) Monthly data 155 (74·2) 258 (46·7) Analytic method Qualitative 146 (69·9) 179 (32·4)	> 10 years	37 (17-7)	87 (15.8)	
Monthly data 155 (74·2) 258 (46·7) Analytic method Qualitative 146 (69·9) 179 (32·4)	Type of RSV data			
Analytic method 146 (69.9) 179 (32.4)	Weekly data	57 (27-3)	294 (53·3)	
Qualitative 146 (69·9) 179 (32·4)	Monthly data	155 (74-2)	258 (46·7)	
	Analytic method			
Quantitative 66 (31·6) 373 (67·6)	Qualitative	146 (69.9)	179 (32·4)	
	Quantitative	66 (31-6)	373 (67-6)	

Threshold-based	54 (25.9)	205 (37·1)	
Coverage-based	8 (3.8)	142 (25·7)	
Model-based	6 (2.9)	26 (4.7)	
RSV case source			
Inpatient	94 (45·0)	152 (27.5)	
Outpatient	14 (6.7)	25 (4.5)	
Both	53 (25.4)	115 (20.8)	
Unknown	48 (23.0)	260 (47·1)	
RSV case definition ^e			
ARI or ILI	82 (39·2)	150 (27·2)	
SARI	23 (11.0)	45 (8.2)	
ALRI	48 (23.0)	59 (10·7)	
Clinical judgement	9 (4·3)	30 (5.4)	
Unknown	70 (33.5)	310 (56·2)	
Testing method ^f			
Virus detection	45 (21.5)	168 (30-4)	
Antigen detection	107 (51-2)	303 (54-9)	
Antibody detection	8 (3.8)	42 (7.6)	
Nucleic acid detection	110 (52·6)	323 (58·5)	
Unknown	33 (15·8)	127 (23.0)	

Note: ARI, acute respiratory infection; ILI, influenza-like illness; SARI, severe acute respiratory infection; ALRI, acute lower respiratory infection

^aAn investigation was identified as an analysis with a specified method on the reported RSV data for the seasonality of RSV activities. Analyses on the same data with different analytic methods were recognized as different investigations. A publication might include several investigations describing the seasonality of RSV activities by analysing different sets of data, or applying different analytic methods, etc. Therefore, the sum of investigations might be greater than the total number of publications.

^bRefers to the publications/investigations with study sites involving more than one continent.

^d Refers to the publications/investigations in which the study period contains the periods both before and after the year when Palivizumab was approved in the study locations.

^e A publication/investigation on RSV seasonality might be based on multiple sources of cases, e.g., ARI, ILI and SARI perhaps were used together or in different combinations to identify patients for RSV testing. Some investigations/studies might be counted multiple times, and the sum of the proportions of publications/investigations from different case definition categories may exceed 100%.

¹ A publication/investigation on RSV seasonality might adopt multiple testing methods for RSV detection. Some investigations/studies might be counted multiple times, and the sum of the proportions of publications/investigations from different testing method categories may exceed 100%.

^c For different locations, the time for palivizumab to be licensed for prophylactic use are different. For the countries where palivzumab has not been licensed, such as China, all the publications/investigations of this country would be recognized as "before palivzumab approved".

Table 2. Associations identified in the linear regression analysis between durations of RSV seasons estimated from quantitative approaches and characteristics of the studies.

Variable	Change in duration of RSV season (months)	95% confidence interval	p-value
Climatic zone			
Temperate region (<-35° or >35°)	0	Referent	
Subtropical region (-35°23·5° or 23·5°- 35°)	1.06	0.45, 1.66	<0.001
Tropical region (-23·5° – 23·5°)	1.65	0.77, 2.54	<0.001
Analysis method			1
Coverage-based method	0	Referent	
Threshold-based method	1.43	0.96, 1.90	<0.001
Model-based method	1.98	-0.99, 4.95	0.19
Meteorological factor			
Daily average mean absolute humidity	0.013	-0.0049, 0.030	0.15

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

and tropical region (equator-23.5°).

FIGURE LEGENDS Figure 1. Flowchart of study identification and selection for the systematic review. Figure 2. Geographic distribution of study locations and the reported RSV seasonal patterns from all included investigations using either quantitative or qualitative approaches. Figure 3. The timing of one-peak RSV seasons reported in investigations using either quantitative or qualitative approaches against the latitude of the study site located in the Northern Hemisphere (NH, centred at the north pole) in panels A, C and E, and Southern Hemisphere (SH, centred at the south pole) in panels B, D and F. The start (A), peak (C) and end (E) of RSV seasons in NH. The start (B), peak (D) and end (F) of RSV seasons in SH. The centre of the radius circles represents the north pole or the south pole (latitude = 90°) and the external border represents the equator (latitude = 0°). The circles were divided by the dashed radiuses into 12 sections to represent 12 months of a year. Two radius circles between the north/south pole and the external border indicating the latitudes at 23.5° and 35° are used to define the temperate region (35°-90°), subtropical region (23.5°-35°)





